CRCM  Vol.3 No.3 , March 2014
Salivary Duct Carcinoma of the Parotid Gland Definitively Diagnosed by Immunohistochemical Examination of Pulmonary Metastases
ABSTRACT

Salivary duct carcinoma (SDC) is a rare, high-grade, aggressive malignancy, as having a morphologic resemblance to ductal carcinoma of the breast. We present here an atypical SDC of the parotid gland in a 63-year-old man that was diagnosed from immunohistochemical findings. The immunohistochemistry was similar in the parotid lesion and pulmonary metastases in autopsy specimens, but only the latter showed a cribriform pattern and comedolike necrosis. Although the parotid tumor was treated with concurrent chemoradiotherapy and adjuvant chemotherapy for over 21 months, the patient died of respiratory failure caused by advanced pulmonary metastases.


Cite this paper
Yonemoto, M. , Onizawa, K. , Yamagata, K. , Hasegawa, S. , Yanagawa, T. and Bukawa, H. (2014) Salivary Duct Carcinoma of the Parotid Gland Definitively Diagnosed by Immunohistochemical Examination of Pulmonary Metastases. Case Reports in Clinical Medicine, 3, 118-121. doi: 10.4236/crcm.2014.33029.
References
[1]   Kleinsasser, O., Klein, H.J. and Hübner, G. (1968) Salivary Duct Carcinoma: A Group of Salivary Gland Tumors Analogous to Mammary duct Carcinoma. Archive für klinische und experimentelle Ohren-Nasenund Kehlkopfheilkunde, 192, 100-105.

[2]   Jaehne, M., Roeser, K., Jaekel, T., et al. (2005) Clinical and Immunohistologic Typing of Salivary Duct Carcinoma: A Report of 50 Cases. Cancer, 103, 2526-2533. http://dx.doi.org/10.1002/cncr.21116

[3]   Guzzo, M., Di Palma, S., Grandi, C., et al. (1997) Salivary Duct Carcinoma: Clinical Characteristics and Treatment Strategies. Head Neck, 19, 126-133.
http://dx.doi.org/10.1002/(SICI)1097-0347(199703)19:2<126::AID-HED7>3.0.CO;2-6

[4]   Lewis, J.E., Mckinney, B.C., Weiland, L.H., et al. (1996) Salivary Duct Carcinoma: Clinicopathologic and Immunohistochemical Review of 26 Cases. Cancer, 77, 223-230.
http://dx.doi.org/10.1002/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N

[5]   Martinez-Barba, E., Cortes-Guardiola, J.A., Torroba-C0aron, A., et al. (1997) Salivary Duct Carcinoma: Clinicopathological and Immunohistochemical Studies. Journal of Cranio-Maxillofacial Surgery, 25, 328-334.
http://dx.doi.org/10.1016/S1010-5182(97)80035-2

[6]   Hellquist, H.B., Karlsson, M.G. and Nilsson, C. (1994) Salivary Duct Carcinoma—A Highly Aggressive Salivary Gland Tumor with over Expression of c-erbB-2. The Journal of Pathology, 172, 35-44.
http://dx.doi.org/10.1002/path.1711720108

[7]   Delgado, R., Vuitch, F. and Albores-Saavedra, J. (1993) Salivary Duct Carcinoma. Cancer, 72, 1503-1512.
http://dx.doi.org/10.1002/1097-0142(19930901)72:5<1503::AID-CNCR2820720503>3.0.CO;2-K

[8]   Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 235, 177-182. http://dx.doi.org/10.1126/science.3798106

[9]   Nabili, V., Tan, J.W., Bhuta, S., et al. (2007) Salivary Duct Carcinoma: A Clinical and Histologic Review with Implications for Trastuzumab Therapy. Head & Neck, 29, 907-912. http://dx.doi.org/10.1002/hed.20614

[10]   Slamon, D.J., Leyland-Jones, B., Shak, S., et al. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. The New England Journal of Medicicne, 344, 783-792.
http://dx.doi.org/10.1056/NEJM200103153441101

 
 
Top